[ad_1]
Pfizer antiviral pill against coronavirus got the green light from European drug regulator, EMA, which it described as helping more adults from Covid 19 seriously ill.
All countries of the world are trying these days to increase their arsenal of tools in the fight against the Omicron variant.
EMA approval allows EU member states to start using the drug.
EMA is also evaluating the application for approval of the pill created by Merck.
The US Food and Drug Administration authorized the day before this firm’s drug against COVID-19 for the group of patients over 18 years of age with high risk.
Earlier, she had given OK a similar treatment of Pfizer, Paxlovid, for high-risk patients over 12 years old.
Merck’s drug, molnupiravir, developed with Ridgeback Biotherapeutics, reduces hospitalizations and deaths by about 30%, according to a clinical trial among high-risk individuals in the early stages of the disease.
Both Merck and Pfizer pills can be promising treatments for those with COVID-19, especially in the face of the rapid spread of Omicron, which in many parts of the world is becoming the dominant variant.
top channel
[ad_2]
Source link
